Key Highlights
- Viatris received FDA approval for Gwyn Lo, a once-weekly combined hormonal contraceptive patch with low-dose estrogen, approved under the 505(b)(2) regulatory pathway.
- The approval was supported by the Phase 3 Luminous Study, which showed a Pearl Index of 4.14 and patch adhesion with only 1.3% of applied systems fully detaching.
- The most common adverse reactions reported included application site irritation, intercycle bleeding, and nausea, each occurring in less than 5% of patients.
- Viatris expects Gwyn Lo to become commercially available later this year, addressing a contraceptive market where unintended pregnancy accounted for 41.6% of pregnancies in 2019.
A New Low-Dose Option Enters the Contraceptive Patch Market
Viatris (NASDAQ:VTRS) has received FDA approval for Gwyn Lo, a once-weekly transdermal combined hormonal contraceptive patch delivering a low dose of estrogen, positioning the product as a discreet, non-invasive, and reversible option for women of childbearing potential. The patch is indicated for women with a body mass index below 30 kilograms per square meter who are appropriate candidates for combined hormonal contraception, delivering norelgestromin at 220 micrograms per day and ethinyl estradiol at 20 micrograms per day.
Company leadership described the approval as building on Viatris's established expertise in transdermal drug delivery systems and its longer-standing presence in women's health, noting that the approved label reflects clinical data demonstrating efficacy specifically in women with a BMI between 25 and just under 30, without additional BMI-based restrictions within that range.
Clinical Trial Data Supports Efficacy and Real-World Adhesion
The approval was granted under the FDA's 505(b)(2) regulatory pathway and supported by results from the Phase 3 Luminous Study, which evaluated contraceptive efficacy, safety, and patch adhesion performance. The trial's primary efficacy endpoint, the Pearl Index measuring pregnancies per 100 woman-years of exposure among women aged 18 to 35, came in at 4.14, with a 95% confidence interval spanning 2.77 to 5.95.
Real-world adhesion performance proved notably strong, with only 1.3% of the nearly 39,790 transdermal systems applied during the year-long trial fully detaching. Cycle control also improved meaningfully over time, with rates of unscheduled bleeding or spotting declining from 34.5% in the first treatment cycle to 20.0% by the thirteenth cycle, alongside a reduction in average bleeding duration from 3.2 days to 2.4 days over the same period. The most common adverse reactions, each occurring in less than 5% of patients, included application site irritation, erythema and pruritus, along with intercycle bleeding, heavy withdrawal bleeding, and nausea.
Addressing a Persistent Gap in Contraceptive Choice
Unintended pregnancy remains a significant public health concern in the United States, accounting for 41.6% of pregnancies recorded in 2019, underscoring the continued need for contraceptive options that align with varying patient preferences. A 2023 survey found that 18.1% of women who had used a contraceptive method changed or discontinued it within the prior 12 months, with nearly 43% of those women citing dissatisfaction with the method itself as the reason for the change.
Gwyn Lo is positioned to address this gap by offering a non-invasive, reversible, low-estrogen-dose option specifically for women who prefer once-weekly administration over daily pills or other contraceptive formats. Separate Phase 1 studies also demonstrated consistent drug delivery across varied real-world conditions, including sauna use, whirlpool exposure, treadmill exercise, and cold-water immersion, suggesting the patch's performance may hold up reliably across a range of everyday activities and environments.
Conclusion
Viatris's FDA approval for Gwyn Lo adds a differentiated low-dose contraceptive patch option to a market where patient dissatisfaction with existing methods remains a persistent driver of discontinuation. With commercial availability expected later this year, the product's combination of demonstrated efficacy, strong real-world adhesion, and manageable safety profile could help address documented gaps in contraceptive choice, though its actual market uptake may depend on how it is positioned relative to existing hormonal contraceptive alternatives once launched.






Please wait processing your request...